Genetic and Histopathologic Characteristics of Interstitial Cystitis
October 25, 2024 updated by: KYU-SUNG LEE, Samsung Medical Center
Genetic and Histopathologic Characteristics of Interstitial Cystitis
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
14
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Seoul, Korea, Republic of, 135-710
- Samsung Medical Center, Sungkyunkwan University School of Medicine
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
- Patients diagnosed with Hunner lesion in Interstitial cystitis and who is scheduled to undergo transurethral resection
- Patients diagnosed with Bladder cancer and who is scheduled to undergo cystectomy
Description
Inclusion Criteria:
- Male and female aged 19 yrs or greater
- Patients diagnosed with Hunner lesion in Interstitial cystitis and who is scheduled to undergo transurethral resection
- Patients diagnosed with Bladder cancer and who is scheduled to undergo cystectomy
Exclusion Criteria:
- Male and female under aged 20 yrs
- A person whose area of bladder cancer is larger than that of the normal area
- A person who is going to have a cystectomy after chemotherapy on bladder cancer
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
normal
|
Obtain the bladder tissue of Interstitial Cystitis and normal during the operation
|
|
Interstitial Cystitis
|
Obtain the bladder tissue of Interstitial Cystitis and normal during the operation
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Genetic differences between ulcer and non-ulcer of bladder in Interstitial Cystitis
Time Frame: 30days
|
30days
|
|
Genetic differences between bladder tissue of Interstitial Cystitis and normal bladder tissue
Time Frame: 30days
|
30days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 31, 2018
Primary Completion (Actual)
December 31, 2023
Study Completion (Actual)
February 29, 2024
Study Registration Dates
First Submitted
May 1, 2018
First Submitted That Met QC Criteria
May 1, 2018
First Posted (Actual)
May 14, 2018
Study Record Updates
Last Update Posted (Actual)
October 29, 2024
Last Update Submitted That Met QC Criteria
October 25, 2024
Last Verified
October 1, 2024
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2018-03-025
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.